Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer-Reference-Cited by-同舟云学术

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Published:2017-04 Issue:4 Volume:28 Page:754-760
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bell R.,Brown J.,Parmar M.,Toi M.,Suter T.,Steger G.G.,Pivot X.,Mackey J.,Jackisch C.,Dent R.,Hall P.,Xu N.,Morales L.,Provencher L.,Hegg R.,Vanlemmens L.,Kirsch A.,Schneeweiss A.,Masuda N.,Overkamp F.,Cameron D.

Funder

F Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/4/754/11121294/mdw665.pdf

Reference32 articles.

1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

2. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

3. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation;Miles;Eur J Cancer,2017